MRI Safety Notes



Introduction
Operating the MR System is an important responsibility. The systems are often multi-million dollar pieces of equipment that require special training and special safety procedures. The certification procedure described below is in force to ensure the safety of all concerned, faculty, staff and patients alike. Safety must be your number one concern at all times while operating this equipment.


To date, over 200 million patients have had MRI examinations. Every year, approximately 10 million patients undergo MRI procedures. MRI has been shown to be extremely safe as long as proper safety precautions are taken. In general, the MRI procedure produces no pain and causes no known short-term or long-term tissue damage of any kind. 

The powerful magnetic field of the scanner can attract certain metallic objects known as 'ferromagnetic' objects, causing them to move suddenly and with great force towards the center of the MR system. This may pose a risk to the patient or anyone in the way of the object. Therefore, great care is taken to prevent ferromagnetic objects from entering the MR system room. It is vital that you remove metallic objects in advance of an MRI exam, including watches, jewelry, and items of clothing that have metallic threads or fasteners.

MRI facilities have screening procedures that, when carefully followed, will ensure that the MRI technologist and radiologist knows about the presence of metallic implants and materials so that special precautions can be taken (see below). In some unusual cases the examination may be canceled because of concern related to a particular implant or device. For example, if an MRI is ordered, it may be canceled if the patient has a ferromagnetic aneurysm clip because of the risk dislodging the clip from the blood vessel. Also, the magnetic field of the scanner can damage an external hearing aid or cause a heart pacemaker to malfunction. If you have a bullet or other metallic fragment in your body there is a potential risk that it could change position, possibly causing injury. 

How to prepare for the MRI examination.
There's no special preparation necessary for the MRI examination. Unless your doctor specifically requests that you not eat or drink anything before the exam, there are no food or drink restrictions. Continue to take any medication prescribed by your doctor unless otherwise directed. 

You won't be allowed to wear anything metallic during the MRI examination, so it would be best to leave watches, jewelry or anything made from metal at home. Even some cosmetics contain small amounts of metals, so it is best to not wear make-up.

In order to prevent metallic objects from being attracted by the powerful magnet of the MR system, you will typically receive a gown to wear during your examination. Items that need to be removed by patients before entering the MR system room include:

-Purse, wallet, money clip, credit cards, cards with magnetic strips
-Electronic devices such as beepers or cell phones
-Hearing aids
-Metal jewelry, watches
-Pens, paper clips, keys, coins
-Hair barrettes, hairpins
-Any article of clothing that has a metal zipper, buttons, snaps, hooks, underwires, or metal threads
-Shoes, belt buckles, safety pins

Before the MRI procedure, you will be asked to fill out a screening form asking about anything that might create a health risk or interfere with imaging. You will also undergo an interview by a member of the MRI facility to ensure that you understand the questions on the form. Even if you have undergone an MRI procedure before at this or another facility, you will still be asked to complete an MRI screening form.

Examples of items or things that may create a health hazard or other problem during an MRI exam include:

-Pacemaker
-Implantable cardioverter defibrillator (ICD)
-Neurostimulator
-Aneurysm clip 
-Metal implant
-Implanted drug infusion device
-Foreign metal objects, especially if in or near the eye
-Shrapnel or bullet wounds
-Permanent cosmetics or tattoos
-Dentures/teeth with magnetic keepers
-Other implants that involve magnets
-Medication patch (i.e., transdermal patch) that contains metal foil

Check with the MRI technologist or radiologist at the MRI center if you have questions or concerns about any implanted object or health condition that could impact the MRI procedure. This is particularly important if you have undergone surgery involving the brain, ear, eye, heart, or blood vessels.

Important Note: If you are pregnant or think that you could be pregnant, you must notify your physician and the radiologist or the MRI technologist at the MRI center prior to the MRI procedure.

Before entering the examining room, any friend or relative that might be allowed to accompany you will be asked questions to ensure that he or she may safely enter the MR system room and will likewise be instructed to remove all metallic objects. Additionally, this individual will need to fill out a screening form.



The List contains information for thousands of implants, devices, materials, and other products. The objects in The List are divided into general categories to facilitate access and review of pertinent information.

To properly utilize The List, particular attention must be given to the information indicated for the highest static magnetic Field Strength used for testing and the Status information indicated for a given Object. The “default” Field Strength indicated for an "MR Safe" implant is 1.5-Tesla.

(Note: These specific terms correspond to the column headings for information compiled in The List). In addition, for certain objects (e.g., those designated as Conditional 5), it will be necessary to refer to specific recommendations on this website or to contact the manufacturer of the implant or device for the latest MRI information, particularly if the implant/device in question is electronically-activated or otherwise an “active” implant. Frequently, specific MRI information is best found at the implant/device company’s website.

The relevant terminology for The List is, as follows:

Object: This is the implant, device, material, or product that underwent evaluation relative to an MR procedure or the MR environment. Information is also provided for the material(s) used to make the object and the manufacturer of the object, if known. The term “SS” refers to stainless steel. Note that there are magnetic and nonmagnetic forms of stainless steel.

Status: This information pertains to the results of the tests conducted for the object. Testing typically included an assessment of magnetic field interactions (i.e., deflection and/or torque) and MRI-related heating, as needed. In some cases, medical products were assessed for induced electrical currents and the impact of an MR procedure or the MR environment on the functional aspects of the object.

Information for each object has been specifically categorized using a Status designation, which indicates the object to be Safe, Conditional, or Unsafe, as follows:

Safe – The object is considered to be safe for the patient undergoing an MR procedure or an individual in the MR environment, with special reference to the highest static magnetic field strength that was used for the MR safety test. The object has undergone testing to demonstrate that it is safe or it is made from material(s) considered to be safe with regard to the MR environment (e.g., plastic, silicone, glass, etc.) or an MR procedure. Refer to additional information for the particular object indicated on this website.

Terminology from the American Society for Testing and Materials (ASTM) International and utilized by the Food and Drug Administration refers to MR safe as an item that poses no known hazards in all MRI environments. Using the current terminology, MR safe items include non-conducting, non-metallic, non-magnetic items such as a plastic Petri dish. 

Conditional – The object may or may not be safe for the patient undergoing an MR procedure or an individual in the MR environment, depending on the specific conditions that are present.

Current terminology from the American Society for Testing and Materials (ASTM) International and utilized by the Food and Drug Administration refers to MR conditional as an item that has been demonstrated to pose no known hazards in a specified MRI environment with specified conditions of use. Field conditions that define the MRI environment include static magnetic field strength, spatial gradient, dB/dt (time varying magnetic fields), radio frequency (RF) fields, and specific absorption rate (SAR). Additional conditions, including specific configurations of the item (e.g., the routing of leads used for a neurostimulation system), may be required. 

The MR conditional information has been sub-categorized to indicate specific recommendations for the particular object, as follows:

Conditional 1 – The object is acceptable for the patient or individual in the MR environment, despite the fact that it showed positive findings for magnetic field interactions during testing. Notably, the object is considered to be “weakly” ferromagnetic, only.

In general, the object is safe because the magnetic field interactions were characterized as “mild” or “weak” relative to the in vivo forces or counter-forces present for the object. For example, certain prosthetic heart valve prostheses and annuloplasty rings showed measurable magnetic field interactions during exposure to the MR systems used for testing, but the magnetic field interactions were less than the forces exerted on the implants by the beating heart.

Additionally, there may be substantial “retentive” or counter-forces provided by the presence of sutures or other means of fixation (e.g., screws, cement, etc.), tissue ingrowth, scarring, or granulation that serve to prevent the object from presenting a risk or hazard to the patient undergoing an MR procedure or an individual in the MR environment.

For a device or product that is used for an MR-guided procedure (e.g., laryngoscope, endoscope, etc.), there may be minor magnetic field interactions in association with the MR system. Eddy currents may also be present. However, the device or product is considered to be acceptable if it is used in its “intended” manner, as specified by the manufacturer. Special attention should be given to the strength of the static magnetic field used for testing the device or product. Functional or operational aspects may need to be considered. Additionally, specific recommendations for the use of the device or product in the MR environment or during an MR procedure (i.e., typically presented in the Product Insert or Instructions for Use) should be followed carefully. See also Conditional 7 information below. 

Conditional 2 – These particular “weakly” ferromagnetic coils, filters, stents, clips, cardiac occluders, or other implants typically become firmly incorporated into the tissue six weeks following placement. Therefore, it is unlikely that these objects will be moved or dislodged by interactions with the magnetic fields of MR systems operating at the static magnetic field strength used for testing. Furthermore, to date, there has been no report of an injury to a patient or individual in association with an MR procedure for these coils, stents, filters, cardiac occluders or other similar implants designated as “Conditional 2”.

Of note is that if the implant is made from a nonmagnetic material (e.g., Phynox, Elgiloy, titanium, titanium alloy, MP35N, Nitinol, etc.), it is not necessary to wait a minimum of six weeks before performing and MR procedure using an MR system operating at 1.5-Tesla or less (in some cases, this may also apply to 3-Tesla MR systems).

Special Note: If there is any concern regarding the integrity of the implant or the integrity of the tissue with regard to its ability to retain the object in place during an MR procedure or during exposure to the MR environment, the patient or individual should not be allowed into the MR environment. 

Conditional 3 – Certain transdermal patches with metallic foil (e.g., Deponit, nitroglycerin transdermal delivery system) or other metallic components, although not attracted to an MR system, have been reported to heat excessively during MR procedures. This excessive heating may produce discomfort or burn a patient or individual wearing a transdermal patch with a metallic component. Therefore, it is recommended that the patch be removed prior to the MR procedure. A new patch should be applied immediately after the examination. This procedure should only be done in consultation with the patient’s or individual’s personal physician responsible for prescribing the transdermal medication patch.

See Safety Info section, Transdermal Medication Patches and Other Drug Delivery Patches

Conditional 4 - This halo vest or cervical fixation device may have ferromagnetic component parts, however, the magnetic field interactions have not been determined. Nevertheless, there has been no report of patient injury in association with the presence of this device in the MR environment at the static magnetic field strength used for MR safety testing. Issues may still be present with regard to MRI-related heating. As such, guidelines provided in the Product Insert or Instructions for Use for a given halo vest or cervical fixation device should be carefully followed. Halo vests and cervical fixation devices made from conducting metals may heat excessively during an MR procedure, resulting in serious patient injury. Contact the manufacturer for further information. Also, refer to recent information for cervical fixation devices, as several have now been evaluated at 3-Tesla.

Conditional 5 - This object is acceptable for a patient undergoing an MR procedure or an individual in the MR environment only if specific guidelines or recommendations are followed (see specific information for a given object on this website and contact the manufacturer for further information). Please refer to the specific criteria for performing the MR procedure by reviewing the information for the object on this website. Consult the manufacturer of the particular device for the latest safety information. Frequently, this information is best found at the company’s website.

A list of biomedical company websites may be found on this website. 

Conditional 6 - This implant/device was determined to be MR-conditional according to the terminology specified in the American Society for Testing and Materials (ASTM) International, Designation: F2503. Standard Practice for Marking Medical Devices and Other Items for Safety in the Magnetic Resonance Environment.

Non-clinical testing demonstrated that the implant/device is MR Conditional. A patient with this implant/device can be scanned safely immediately after placement under the following conditions:

- Static magnetic field of 3-Tesla or less

- Maximum spatial gradient magnetic field of 720-Gauss/cm or less

- Maximum MR system reported whole-body-averaged specific absorption rate (SAR) of 3-W/kg for 15 minutes of scanning.

In non-clinical testing, the implant/device produced a temperature rise of less than or equal to 3.0 degrees C at a maximum MR system-reported whole body averaged specific absorption rate (SAR) of 3-W/kg for 15-minutes of MR scanning in a 3-Tesla MR system using a transmit/receive body coil (Excite, Software G3.0-052B, General Electric Healthcare, Milwaukee, WI).

MR image quality may be compromised if the area of interest is in the exact same area or relatively close to the position of the implant/device. Therefore, optimization of MR imaging parameters to compensate for the presence of this implant/device may be necessary.

Attention: Contact the manufacturer of this implant/device for further information, as needed.

Conditional 7 - Important Note: This device is not intended for use during the operation of an MR system for an MR procedure. That is, this device should not be inside of the bore of the MR system, exposing this device to the time-varying and RF fields activated during an MR procedure.

Attention: Contact the manufacturer of this implant/device for further information.

Conditional 8 – Note: This information pertains to an implant/device that has MRI labeling at 1.5-Tesla and 3-Tesla. In some cases, it may pertain to a single and two-overlapped version of a stent. Contact the manufacturer for additional MRI information, as needed.

The implant/device was determined to be MR-conditional according to the terminology specified in the American Society for Testing and Materials (ASTM) International, Designation: F2503. Standard Practice for Marking Medical Devices and Other Items for Safety in the Magnetic Resonance Environment.

Non-clinical testing demonstrated that the implant/device is MR Conditional. A patient with this implant/device can be scanned safely immediately after placement under the following conditions:

For magnetic field interactions,

-Static magnetic field of 3-Tesla or less

-Maximum spatial gradient magnetic field of 720-Gauss/cm or less

MRI-Related Heating
In non-clinical testing, the implant/device produced the following temperature rises during MRI performed for 15-min in 1.5-Tesla (1.5-Tesla/64-MHz, Magnetom, Siemens Medical Solutions, Malvern, PA. Software Numaris/4, Version Syngo MR 2002B DHHS) and 3-Tesla (3-Tesla/128-MHz, Excite, Software G3.0-052B, General Electric Healthcare, Milwaukee, WI) MR systems, using MR system reported, whole body averaged SAR of 3-W/kg or less, as follows:

Highest temperature change MRI Condition

Less than or equal to 4.0 degrees C 1.5-T/64-MHz

Less than or equal to 4.0 degrees C 3-T/128-MHz

Artifact Information
MR image quality may be compromised if the area of interest is in the exact same area or relatively close to the position of the implant/device. Therefore, optimization of MR imaging parameters to compensate for the presence of this implant/device may be necessary.

Attention: Contact the manufacturer of this implant/device for further information.

Terminology from the American Society for Testing and Materials (ASTM) International and utilized by the Food and Drug Administration refers to MR Unsafe as an item that is known to pose hazards in all MRI environments. MR Unsafe items include magnetic items such as a pair of ferromagnetic scissors. 

Unsafe 1 – The object is considered to pose a potential or realistic risk or hazard to a patient or individual in the MR environment primarily as the result of movement or dislodgment of the object. Other hazards may also exist. Therefore, in general, the presence of this object is considered to be a contraindication for an MR procedure and/or for an individual to enter the MR environment. Note that the “default” static magnetic field strength for an unsafe implant or device is 1.5-Tesla.

Unsafe 2 – This object displays only minor magnetic field interactions which, in consideration of the in vivo application of this object, is unlikely to pose a hazard or risk in association with movement or dislodgment. Nevertheless, the presence of this object is considered to be a contraindication for an MR procedure or for an individual in the MR environment. Potential risks of performing an MR procedure in a patient or individual with this object are related to possible induced currents, excessive heating, or other potentially hazardous conditions. Therefore, it is inadvisable to perform an MR procedure in a patient or individual with this object.

For example, although certain cardiovascular catheters and accessories typically do not exhibit magnetic field interactions, there are other mechanisms whereby these devices may pose a hazard to the patient or individual or in the MR environment (e.g., excessive MRI-related heating).

The Swan-Ganz thermodilution catheter (and other similar catheters) displays no attraction to the MR system. However, there has been a report of a Swan-Ganz catheter that “melted” in a patient during an MR procedure. Therefore, the presence of this cardiovascular catheter and any other similar device is considered to be a contraindication for a patient undergoing an MR procedure.

Field Strength – This is the highest strength of the static magnetic field of the MR system that was used for safety testing of the object. In most cases, a 1.5-Tesla MR system was used for testing. However, there are some objects that were tested at field strengths lower (e.g., 0.15-Tesla) or higher (e.g., 3-Tesla) than 1.5-Tesla. Note that the “default” field strength for an unsafe implant or device is 1.5-Tesla.

There are MR systems with static magnetic field strengths that exceed 3.0-Tesla (i.e., as high as 8-Tesla or 9.4-Tesla). Some objects have been assessed to determine the relative amount of magnetic field interactions in association with these very high-field-strength MR systems.

Important Note: An object that exhibits only “mild” or “weak” magnetic field interactions in association with exposure to a 1.5-Tesla MR system may be attracted with sufficient force by a higher field strength scanner (e.g., 3-Tesla), potentially posing a risk to a patient or individual.

Therefore, careful consideration must be given to each object relative to the static magnetic field strength of the MR system used for testing as well as the conditions that are present for the patient or individual under consideration prior to exposure to the MR environment. Furthermore, for implants and devices that have an elongated shape or form a loop of a certain diameter, MRI-related heating may be of concern.

Reference – This is the peer-reviewed publication or other documentation used for the MRI safety information indicated for a particular object.

*Terminology Applied to Implants and Devices
For a comprehensive explanation, see Shellock FG, Woods TO, Crues JV. MRI labeling information for implants and devices: Explanation of terminology. Radiology 2009;253:26-30 (available as a PDF file on www.IMRSER.org) 


Use of Terminology
The current MRI labeling terminology is intended to help elucidate matters related to biomedical implants and devices to ensure the safe use of MRI technology. Notably, this terminology (i.e., MR safe, MR conditional, and MR unsafe) has not been applied retrospectively to implants and devices that previously received U.S. Food and Drug Administration (FDA) approved labeling using the terms “MR safe” or “MR compatible” (i.e., this applies to those objects tested prior to December, 2005). Accordingly, this should be understood to avoid undue confusion regarding the matter of MRI-related labeling for “older” vs. “newer” implants, or those that have undergone retesting.

Fetal MRI Safety


Safety of Fetal MRI
United States Food and Drug Administration guidelines  require labeling of MRI devices to indicate that the safety of MRI with respect to the fetus “has not been established.” Safety concerns arise for both mother and fetus. Maternal safety concerns are the same as for a nonpregnant patient and are addressed by standard MRI screening. Fetal safety concerns are related to teratogenesis and acoustic damage.
Most studies suggest MRI during pregnancy is safe , but several animal studies have raised the possibility of teratogenetic effects in early pregnancy . Although these studies may not be applicable to humans or may represent statistical quirks, they suggest that a cautious approach to adopting the use of MRI in women during the first trimester may be advisable. The guidelines of the National Radiological Protection Board in the United Kingdom state, “It might be prudent to exclude pregnant women during the first three months of pregnancy.” An additional concern in the first trimester is the underlying relatively high rate of spontaneous abortion during this period. An MRI study could be coincidentally followed by a spontaneous abortion that might appear iatrogenic to the patient. That said, when a strong clinical indication has been established, MRI is probably still preferable to any study involving ionizing radiation 
The loud noises generated by the coils of the MR scanner as they are subjected to rapidly oscillating electromagnetic currents could potentially cause acoustic damage to the fetus. Two reports from the United Kingdom provide reassuring clinical and experimental evidence that the risk of acoustic injury is negligible. In summary, pregnant women in the second and third trimester can be reassured that MRI poses no known risk to the fetus. Although safety has not been positively established, any hazard appears negligible and is outweighed by the potential diagnostic benefit. A more cautious approach should be taken when MRI is required during the first trimester.

While the long-term safety of MRI has not been fully established, it is believed, in general, that the benefit it provides in fetal management far outweighs any theoretical risks. No adverse biological effects have been reported at the energies currently delivered with MRI.Whether or not to obtain written consent reflects institutional bias: at Children's Hospital Boston, consent is no longer obtained for performance of routine fetal MRI, while at Massachusetts General Hospital, it is. Most imaging occurs at or after 18 weeks' gestation, when fetal size and motion first allow reasonable visualization with current MRI techniques, avoiding exposure during the peak of organogenesis. Gadolinium is not administered.

Many studies have shown that fetal MRI examination is not associated with any major deleterious effects.  No health risks have been reported at field strength of 1.5-Tesla (1.5-T). No adverse outcomes have been observed in pregnant MRI workers. The Safety Committee of the Society for MRI has concluded that prenatal MRI is indicated when other nonionizing diagnostic imaging methods are inadequate or when MRI examination can provide important information that would otherwise require the use of ionizing radiation. There is currently no data regarding the level of acoustic noise experienced by the fetus during the MRI procedure. The use of gadolinium is not recommended because of the need to avoid potential deleterious effects on the fetus.  The National Radiation Protection Board and the Food and Drug Administration have approved MRI only after the first trimester. The safety of the newer techniques of diffusion-weighted imaging (DWI), diffusion tensor imaging (DTI) , MRI spectroscopy (MRS), and functional MRI (F-MRI) has not yet been proven.


GAOLINIUM OVERVIEW NSF & NFD


Gadolinium-Based Contrast Agents (GBCA) are intravenous drugs used in diagnostic imaging procedures to enhance the quality of magnetic resonance imaging (MRI) or magnetic resonance angiography (MRA).



There are some cases during an MRI scan that requires a contrast agent injected into the patient. A contrast MRI agent (or dye) is a substance that is more susceptible to the magnetic fields of produced during the scan, hence, producing a better image. Of the different contrast dyes, gadolinium is the most well known.
Gadolinium is a metal with very strong paramagnetic properties. In other words, it aligns very easily with an external magnetic field, which allows for the MRI to scan your body much more efficiently. Gadolinium can be very deadly to humans as an ion, so to make it safe to use it must go through chelation - a process that will bind gadolinium to other molecular compounds. There are currently five FDA approved gadolinium contrast agents:
- Magnevist
- Omniscan
- OptiMARK
- MultiHance
- ProHance
Fortunately, under most circumstances, there is no potential danger of being injected with gadolinium. The concentrations are kept low to prevent any side effects and the kidneys will be able to flush out the dye in time.
The real problem is for people without properly functioning kidneys. There is evidence that links gadolinium contrast agents to the cause of NSF, or nephrogenic systemic fibrosis. NSF is a potentially fatal disease that causes excessive fibrous tissue to grow. Consequently, your skin can become very tight and painful and your joint mobility can become extremely limited. If your kidneys are not able to purge the dye from your body, you are at great risk of being stricken with NSF.

What is gadolinium contrast medium?

When injected into the body, gadolinium contrast medium makes certain tissues, abnormalities or disease processes more clearly visible on a magnetic resonance imaging (MRI) scans. Gadolinium based contrast medium is sometimes called an MRI contrast medium or agent.
Gadolinium contrast medium contains complex molecules, that is, an arrangement of atoms (the smallest portion into which an element can be divided and retain its properties) held together by chemical bonds. The chemical bonds are made of a gadolinium ion (the MRI active part) and a carrier molecule. A carrier molecule is called a chelating agent, which modifies the distribution of gadolinium within the body, to overcome its toxicity while maintaining its contrast properties. It is injected intravenously (injected into a vein) as part of an MRI scan.

Gadolinium is a paramagnetic metal ion. Paramagnetic ions, such as gadolinium, move differently within a magnetic field.  This trait makes gadolinium useful for magnetic resonance imaging (MRI).

GBCAs are manufactured by a chelating process, a procedure in which large organic molecules form a stable complex around the gadolinium. The chelate reduces the chances of toxicity that could result from exposure to gadolinium. This stable complex is eliminated predominantly via the kidneys.

GBCAs are approved by FDA for use with MRI as a contrast agent to provide an improved image of body organs and tissues.
GBCAs are also used for magnetic resonance angiography (MRA), an imaging procedure used to evaluate blood vessels.  FDA has not approved GBCAs for use in MRA.



 Use of gadolinium contrast medium

Gadolinium contrast medium is used in up to 30% of MRI scans to improve the clarity of the scanned images or pictures of your body’s internal structures. This improves the diagnostic accuracy of the MRI scan. For example, it increases the visibility of inflammation, a tumour or growth, blood vessels, cardiac (heart) muscle scarring and assesses the blood flow to organs such as the brain and heart.
Usually, you will be advised before you have the MRI scan that part of the way through the scan, gadolinium contrast medium will be injected. The technologist who performs the MRI scan, a nurse or a radiologist (a specialist doctor) will give you the injection.
Sometimes, based on the notes provided by your doctor on your referral, it will not be expected that you require gadolinium but after some of the scanning is done, the radiologist may decide that gadolinium would help to make the images clearer. If you are told part of the way through your scan that gadolinium will be needed, you should not worry that this is an indication that something serious is wrong. Most often this is just being done to make the images clearer and therefore easier to interpret so that the diagnosis is more definite.


 Benefits of gadolinium contrast medium injections



MRI contrast agents (usually gadolinium based contrast medium) improve diagnostic accuracy in some conditions such as inflammation and infectious diseases of the brain, spine, soft tissues and bones by making it easier for the radiologist to see what and where the problem is. The nature and extent of some cancers and benign tumours is best seen and assessed using gadolinium contrast medium.
Angiography scans (showing the function of blood vessels as it is happening on a video screen) can be performed using gadolinium contrast medium and evaluation of many myocardial (heart) abnormalities can only be fully assessed using gadolinium contrast medium.

Risks of gadolinium contrast medium injections

Gadolinium contrast medium is generally very safe. Side effects or reactions are uncommon but may occur. The most common adverse reactions are brief headache, nausea (feeling sick) and dizziness for a brief time following the injection. This occurs in 1% to 5% of contrast injections. Infrequently, a feeling of coldness may occur at the injection site.
Allergic (anaphylactic) reactions to gadolinium contrast medium have occurred but are extremely rare.  These severe reactions, which may involve difficulty breathing and swelling of the lips and mouth, occur in about 1 in every 10,000 people who have gadolinium. These severe reactions generally respond very well to emergency drug treatment. This treatment is given while in the MRI department of the hospital or private radiology practice.
In patients with normal kidney function most of the gadolinium contrast medium injected is almost entirely passed out in the urine within 24 hours.
Gadolinium contrast medium should be avoided in patients with reduced kidney function or kidney failure (either chronic or acute), and hepatorenal syndrome (a condition involving reduced function of liver and kidneys).
Nephrogenic systemic fibrosis (NSF), a debilitating disease resulting in skin contractures (or localised skin thickening and tightening) and internal organ damage has occurred with some gadolinium based contrast agents in a minority of patients who had pre-existing severe kidney function abnormalities.
If you are pregnant or think you may be pregnant please inform your doctor prior to having the procedure so that your doctor can consider and talk to you about any risks and benefits of having gadolinium for you and your unborn baby.
If you are breast feeding it is safe to continue normal breast feeding after the gadolinium contrast medium has been given. There is no requirement to express and dispose of breast milk or to withhold breast feeding. The amount of gadolinium used is so small and rapidly passes out of the body that it does not represent any danger to your child.
If you have any concerns about the use of gadolinium, please discuss these with your referring doctor and the staff where you are having this procedure.


 SIDE EFFECTS OF GADOLINIUM


The most common side effects of headache, nausea and dizziness occur in a small minority of patients only but if they do occur they will be noticed within a few minutes of the injection. Allergic reactions will tend to occur immediately, within several minutes of the injection, when a patient is most likely in the scanner or still in the radiology practice or hospital.
Nephrogenic systemic fibrosis (NSF) is a rare condition associated with gadolinium contrast agents administered to patients with severe renal (kidney) disease. Its onset occurs days or weeks after administration of the agent with almost all cases occurring within six months of the last dose. The use of these agents is generally avoided in patients at risk of NSF.




 What is Nephrogenic Systemic Fibrosis (NSF)?


NSF was first described in the medical literature in 2000. The first case of NSF was identified in 1997. The cause of NSF is unknown but it has been reported only in patients who have severe kidney disease.  NSF causes fibrosis of the skin and connective tissues throughout the body. Patients develop skin thickening that may prevent bending and extending joints, resulting in decreased mobility of joints. NSF usually starts in the lower extremities. Fibrosis can also develop in the diaphragm, muscles in the thigh and lower abdomen, and lung vessels. Over time, NSF becomes worse and can cause death.
Nephrogenic systemic fibrosis (NSF) is also known as nephrogenic fibrosing dermopathy (NFD). With this disorder, patients generally experience a painful hardening of the skin and underlying muscles, especially in the arms and legs. The skin will often take on a "woody" or "orange peel" appearance. In addition to the skin hardening, contracture of joints such as ankles, knees, hips, elbows, wrists, and fingers also can occur, which in turn severely limits range of motion and leads to disability. It is now known that the same fibrosis that NSF causes in the skin and underlying muscles also can be found in the heart, lungs, and other internal organs. NSF is diagnosed by the patient having a "punch" biopsy, which is typically performed by a dermatologist.



 INDICATIONS FOR NSF

  • Skin and eyes
    • Swelling, hardening and tightening of your skin
    • Reddened or darkened patches on the skin
    • Burning or itching of your skin
    • Yellow raised spots on the whites of your eyes
  • Bones and muscles
    • Stiffness in your joints; problems moving or straightening arms, hands, legs, or feet
    • Pain deep in your hip bones or ribs
    • Muscle weakness

Gadolinium-based MRI contrast agents and Nephrogenic Systemic Fibrosis

Contrast-enhanced MRIs are a relatively common medical procedure, but several of the contrast agents used with MRIs have been linked to a severe condition called nephrogenic systemic fibrosis (NSF). Gadolinium is a highly toxic heavy metal that is contained in MRI contrast agents. The toxicity of gadolinium in these contrast agents is designed to be neutralized by binding it to a chemical called a chelator. However, if the chelator does not securely hold the gadolinium throughout the time it is in the body, the toxic gadolinium is released and causes NSF. Because renal failure patients take longer to excrete the drug, it is this population of patients who are most commonly affected with NSF.

What MRI contrast agents are associated with NSF?

There are five FDA approved gadolinium contrast agents; however, only three of these contrast agents have been credibly implicated in cases of nephrogenic systemic fibrosis. These three gadolinium MRI contrast agents are Omniscan (GE Healthcare), Optimark (Covidien/Mallinckrodt), and Magnevist (Bayer Healthcare). All three of these contrast agents share a common linear design for their chelator that is intended to bind the gadolinium. Other contrast agents use a safer chelator design that builds a "cage" around the gadolinium. These "macrocyclic" contrast agents have not been linked to cases of NSF. In fact, the only proven cause of NSF is exposure to one of these three contrast agents with the linear design.
Five gadolinium-based contrast agents are approved by the FDA for use during an MRI. The trade names for these products are:
  • Omniscan
  • OptiMARK
  • Magnevist
  • ProHance
  • MultiHance
None of these agents are approved by the FDA for MRA. The dose of gadolinium-based contrast agent given to patients undergoing an MRA is often higher (up to three times) than the approved dose for MRI.

Seeking compensation if you have NSF


If you have been diagnosed with nephrogenic systemic fibrosis, you may be eligible to collect money damages. The gadolinium attorneys at Spangenberg, Shibley & Liber have been leaders in the court litigation against the pharmaceutical companies whose MRI contrast agents have been linked to NSF. Spangenberg, Shibley & Liber partners Peter J. Brodhead and William Hawal have been appointed to serve as Plaintiffs' Liaison Counsel for all of the Federal Court litigation, which is centered here in Cleveland, Ohio. Mr. Brodhead and Mr. Hawal also are actively participating in the taking of evidence in these cases.
To find out if you have a case Call 1-888-633-0360 or Contact one of these a gadolinium lawyers.



Popular Posts